Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pitfalls of using polymerase chain reaction-based assays for JAK2 and CALR exon 9 variant testing in myeloproliferative neoplasms: Knowing when to go the extra mile!

American journal of clinical pathology - 1 Feb 2024

Krishnamurthy Kritika, Chai Jiani, Wang Yanhua, Naeem Rizwan, Goldstein D Yitzchak

Abstract excerpt

OBJECTIVES: The BCR::ABL1 negative myeloproliferative neoplasms are sequentially tested for JAK2 p.V617F, followed by CALR exon 9 pathogenic variants. Historically, these variants were thought to be mutually exclusive. However, recent reports indicate coexisting JAK2 p.V617F and CALR exon 9 somatic variants. METHODS: Analysis of JAK2 p.V617F and CALR exon 9 variant was performed by polymerase chain reaction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Exons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CALR gene

Share to Janus Kinase 2

Share to Mutation

Share to Myeloproliferative Disorders

Share to Neoplasms

Share to Polymerase Chain Reaction

Source

Identifiers

PMID: 37788380
DOI: 10.1093/ajcp/aqad122

Genes

CALR
JAK2
ABL1
BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pitfalls of using polymerase chain reaction-based assays for JAK2 and CALR exon 9 variant testing in myeloproliferative neoplasms: Knowing when to go the extra mile!PMID 37788380Read ↗

Pitfalls in CALR exon 9 mutation detection: A single-center experience in 571 positive patients.Semantic proximity Read ↗

Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.Semantic proximity Read ↗

Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.Semantic proximity Read ↗

Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALRSemantic proximity Read ↗

Development and validation of CALR mutation testing for clinical diagnosis.Semantic proximity Read ↗

Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?Semantic proximity Read ↗

A comparison of sequential polymerase chain reaction–based cascade testing vs next-generation sequencing in molecular profiling of myeloproliferative neoplasms: improving testing strategies in light of evolving molecular landscapesSemantic proximity Read ↗

Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms.Semantic proximity Read ↗

The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasmsSemantic proximity Read ↗

A novel molecular assay using hybridisation probes and melt curve analysis for CALR exon 9 mutation detection in myeloproliferative neoplasms.Semantic proximity Read ↗

False-negative CALR mutation in a suspected myeloproliferative neoplasm: identification, resolution and corrective action.Semantic proximity Read ↗

Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.